Bio-Techne (TECH)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$70.61-0.44%
Close 2026-07-07 · 1-day change
Reading TECH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TECH free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading TECH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TECH free→QuarterlyIQ Insights · TECH
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On June 25, 2026, Bio-Techne Corporation, a Minnesota corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“ Parent ”), and EMD Holdings NewCo, Inc., a Minnesota corporation and a wholly-owned subsidiary of Parent (“ Merger Sub ”). The Merger Agreement provides that, on the terms and subject to the conditions of the Merg…
Retention bonuses were approved for named executive officers in connection with a contemplated Merger.
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing of Bio-Techne, whether made before, on, or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. Cautionary Statement Regarding Forward-Looking Statements This communication may contain forward-looking statements based on current assumptions and forecasts made by Merck KGaA, Darm…
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on May 6, 2026, describing the results of operations for the quarter and nine months ended March 31, 2026, and its financial condition as of March 31, 2026 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…
Other Events A copy of the press release issued by Bio-Techne Corporation on May 6, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2.
President of Bio-Techne's Diagnostics and Spatial Biology Segment — Dr. Matt McManus: Dr. Matt McManus is transitioning from his role as President of Bio-Techne's Diagnostics and Spatial Biology Segment.
Other Events A copy of the press release issued by Bio-Techne Corporation on February 4, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on February 4, 2026, describing the results of operations for the quarter and six months ended December 31, 2025, and its financial condition as of December 31, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Other Events A copy of the press release issued by Bio-Techne Corporation on November 5, 2025, announcing a cash dividend is attached hereto as Exhibit 99.2.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation (the “Company”) on November 5, 2025, describing the results of operations for the quarter ended September 30, 2025 and its financial condition as of September 30, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Other Events A copy of the press release issued by Bio-Techne Corporation on August 6, 2025 announcing a cash dividend is attached hereto as Exhibit 99.2.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on August 6, 2025, describing the results of operations for the quarter and year ended June 30, 2025, and its financial condition as of June 30, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…
Other Events A copy of the press release issued by Bio-Techne Corporation on May 7, 2025 announcing a cash dividend and share repurchase program is attached hereto as Exhibit 99.2.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on May 7, 2025, describing the results of operations for the quarter ended March 31, 2025, and its financial condition as of March 31, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise sub…
Regulation FD Disclosure. On April 30, 2025, the Board of Directors of Bio-Techne Corporation (the “ Company ”) authorized a share repurchase program (the “ Share Repurchase Program ”), pursuant to which the Company may, from time to time, purchase shares of its common stock for an aggregate repurchase not to exceed a total of $500,000,000. This replaces the Company’s previous stock repurchase authorization approved by the Board on February 2, 2022. There is no time limit on the Share Repurch…
Charles R. Kummeth: Arbitration ruling required the company to pay Mr. Kummeth a significant amount due to an administrative error.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on February 5, 2025, describing the results of operations for the quarter ended December 31, 2024, and its financial condition as of December 31, 2024 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or ot…
Director — Dr. Amy Herr: Dr. Amy Herr was appointed to the Board of Directors as part of a routine director replacement process.
Other Events A copy of the press release issued by Bio-Techne Corporation on February 5, 2025 announcing a cash dividend is attached hereto as Exhibit 99.2. A copy of the press release issued by Bio-Techne Corporation on February 4, 2025, announcing Dr. Herr’s appointment is attached hereto as Exhibit 99.3.
James Hippel: Compensatory arrangement to address a stock plan administrative error.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation (the “Company”) on October 30, 2024, describing the results of operations for the quarter ended September 30, 2024 and its financial condition as of September 30, 2024 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Other Events A copy of the press release issued by Bio-Techne Corporation on October 30, 2024, announcing a cash dividend is attached hereto as Exhibit 99.2.
Other Events A copy of the press release issued by Bio-Techne Corporation on August 7, 2024 announcing a cash dividend is attached hereto as Exhibit 99.2.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on August 7, 2024, describing the results of operations for the quarter and year ended June 30, 2024, and its financial condition as of June 30, 2024 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…
Other Events A copy of the press release issued by Bio-Techne Corporation on May 1, 2024 announcing a cash dividend is attached hereto as Exhibit 99.2.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.